- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Financially Fit Penny Stocks
Australian Pharmaceuticals & Biotech Financially Fit Penny Stocks
Results
50
A Penny Stocks screener, typically smaller or younger companies trading at a price below 5, with a focus on solid financial health that should present companies with a lower risk profile than other early-stage businesses
50 companies
EZZ Life Science Holdings
Market Cap: AU$74.5m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$1.58
7D
19.7%
1Y
87.0%
NeuroScientific Biopharmaceuticals
Market Cap: AU$7.5m
Engages in the research and development of novel peptide-based pharmaceutical products.
NSB
AU$0.046
7D
31.4%
1Y
-22.0%
Little Green Pharma
Market Cap: AU$37.9m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.12
7D
-4.2%
1Y
-17.9%
Medical Developments International
Market Cap: AU$52.4m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.45
7D
-5.3%
1Y
-17.4%
Aroa Biosurgery
Market Cap: AU$146.6m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.41
7D
6.6%
1Y
-20.6%
Vita Life Sciences
Market Cap: AU$99.7m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$1.77
7D
-1.9%
1Y
-26.6%
Genetic Signatures
Market Cap: AU$105.6m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.41
7D
1.2%
1Y
-41.4%
Acrux
Market Cap: AU$9.0m
Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
ACR
AU$0.023
7D
4.5%
1Y
-60.3%
Radiopharm Theranostics
Market Cap: AU$51.3m
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
RAD
AU$0.022
7D
4.8%
1Y
-51.1%
Botanix Pharmaceuticals
Market Cap: AU$705.6m
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
BOT
AU$0.40
7D
6.8%
1Y
75.6%
Arovella Therapeutics
Market Cap: AU$92.3m
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.078
7D
-3.7%
1Y
-32.2%
Immuron
Market Cap: AU$14.9m
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
IMC
AU$0.064
7D
-3.0%
1Y
-36.0%
PYC Therapeutics
Market Cap: AU$567.5m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.03
7D
1.5%
1Y
8.4%
Actinogen Medical
Market Cap: AU$94.0m
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
ACW
AU$0.03
7D
7.1%
1Y
0.003%
Biotron
Market Cap: AU$4.0m
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
BIT
AU$0.003
7D
0%
1Y
-95.8%
Alterity Therapeutics
Market Cap: AU$59.9m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.007
7D
-12.5%
1Y
40.0%
Immutep
Market Cap: AU$327.5m
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.23
7D
-2.1%
1Y
-32.9%
LTR Pharma
Market Cap: AU$69.7m
A biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
LTP
AU$0.39
7D
5.5%
1Y
37.5%
Cynata Therapeutics
Market Cap: AU$44.1m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.20
7D
0%
1Y
-7.1%
Percheron Therapeutics
Market Cap: AU$13.0m
Engages in the research and development of novel antisense pharmaceuticals in Australia.
PER
AU$0.012
7D
20.0%
1Y
-84.2%
Noxopharm
Market Cap: AU$24.8m
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.
NOX
AU$0.085
7D
23.2%
1Y
37.1%
Invion
Market Cap: AU$7.6m
A clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
IVX
AU$0.098
7D
-2.0%
1Y
-80.4%
Chimeric Therapeutics
Market Cap: AU$8.1m
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
CHM
AU$0.005
7D
0%
1Y
-85.3%
Amplia Therapeutics
Market Cap: AU$20.2m
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
ATX
AU$0.052
7D
-7.1%
1Y
-14.8%
Paradigm Biopharmaceuticals
Market Cap: AU$122.7m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.29
7D
-4.9%
1Y
1.8%
Patrys
Market Cap: AU$6.2m
Develops and commercializes antibody technologies for the treatment of cancer in Australia.
PAB
AU$0.003
7D
50.0%
1Y
-66.7%
Race Oncology
Market Cap: AU$160.7m
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.
RAC
AU$0.93
7D
-10.2%
1Y
-33.5%
Tissue Repair
Market Cap: AU$14.5m
A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.
TRP
AU$0.25
7D
2.0%
1Y
4.2%
Emyria
Market Cap: AU$15.2m
Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.
EMD
AU$0.03
7D
3.4%
1Y
-46.4%
Clarity Pharmaceuticals
Market Cap: AU$539.9m
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.
CU6
AU$1.90
7D
14.8%
1Y
-29.9%
Invex Therapeutics
Market Cap: AU$5.3m
A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
IXC
AU$0.07
7D
0%
1Y
-15.7%
Firebrick Pharma
Market Cap: AU$18.0m
Engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia.
FRE
AU$0.079
7D
0%
1Y
-7.1%
OncoSil Medical
Market Cap: AU$18.4m
A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe.
OSL
AU$0.005
7D
25.0%
1Y
-28.6%
Anatara Lifesciences
Market Cap: AU$1.3m
Engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia.
ANR
AU$0.006
7D
0%
1Y
-85.7%
Genetic Technologies
Market Cap: AU$5.7m
A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
GTG
AU$0.039
7D
0%
1Y
-68.8%
Argenica Therapeutics
Market Cap: AU$87.1m
A biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia.
AGN
AU$0.68
7D
1.5%
1Y
17.2%